Showing results (281-290 of 375) with videos related to
Sort By:
Pageof 38
Advances in Therapy|August 25, 2011
Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UKStephen C L Gough, Cristóbal Belda-Iniesta, Christopher Poole, et al.Diabetologia|August 19, 2009
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialD Russell-Jones, A Vaag, O Schmitz, et al.Biochimica Et Biophysica Acta|April 29, 2000
Functional expression in Pichia pastoris of human and rat intrinsic factorJ Wen, M B Kinnear, M A Richardson, et al.Clinical Medicine (London, England)|July 26, 2020
Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UKHarry Knights, Nikhil Mayor, Kristina Millar, et al.The Journal of Clinical Endocrinology and Metabolism|June 30, 2012
Insulin-sensitizing effects on muscle and adipose tissue after dietary fiber intake in men and women with metabolic syndromeM Denise Robertson, John W Wright, Emmanuelle Loizon, et al.Diabetes|September 1, 1997
rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDMP V Carroll, M Umpleby, G S Ward, et al.Diabetes, Obesity & Metabolism|May 15, 2015
Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?D Russell-Jones, T Danne, K Hermansen, et al.Journal of Computer Assisted Tomography|February 10, 2000
The identification of cerebral volume changes in treated growth hormone-deficient adults using serial 3D MR image processingE R Denton, M Holden, E Christ, et al.Diabetes Technology & Therapeutics|July 31, 2025
Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring-Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6Thomas Danne, Susanne Engberg, Concetta Irace, et al.Diabetes, Obesity & Metabolism|September 15, 2022
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetesAthena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, et al.Pageof 38